Scarica l'app Stockscreener
9.74
1.99%
0.19
Dopo l'orario di chiusura:
9.74
Precedente Chiudi:
$9.55
Aprire:
$9.71
Volume 24 ore:
489.20K
Relative Volume:
0.37
Capitalizzazione di mercato:
$642.55M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-6.1646
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
-9.23%
1M Prestazione:
-2.50%
6M Prestazione:
+40.35%
1 anno Prestazione:
+154.31%
Intervallo 1D:
$9.615
$10.00
Intervallo di 1 settimana:
$9.515
$11.11
Portata 52W:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
9.74 | 630.02M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Iniziato | JP Morgan | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Decliners Report: Can Fulcrum Therapeutics Inc maintain sales growthJuly 2025 PreEarnings & High Return Stock Watch Alerts - baoquankhu1.vn
Insider Sell: Robert Gould Sells 15,000 Shares of Fulcrum Therap - GuruFocus
Sectors Review: Is Fulcrum Therapeutics Inc stock undervalued right nowWeekly Profit Summary & Long-Term Capital Growth Ideas - baoquankhu1.vn
Pharma News: Can Fulcrum Therapeutics Inc maintain sales growthIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Can Fulcrum Therapeutics Inc disrupt its industry2025 Support & Resistance & Precise Swing Trade Alerts - baoquankhu1.vn
Can Fulcrum Therapeutics Inc keep up with sector leadersJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Will Fulcrum Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Momentum & Consistent Return Investment Signals - mfd.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Exploring an 82% Potential Upside Amid Clinical Innovations - DirectorsTalk Interviews
Published on: 2026-01-29 20:30:44 - baoquankhu1.vn
Aug Setups: Will ESNT outperform tech stocksPortfolio Profit Report & Intraday High Probability Alerts - baoquankhu1.vn
Rally Mode: Can Fulcrum Therapeutics Inc. keep up with sector leaders2025 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
Trend Report: What is the target price for ALKS stock2025 Year in Review & Fast Gaining Stock Reports - baoquankhu1.vn
Is Fulcrum Therapeutics Inc benefiting from innovation trendsCPI Data & Weekly Top Gainers Trade List - baoquankhu1.vn
Big Money Moves: Can Fulcrum Therapeutics Inc deliver alphaProduct Launch & Safe Entry Momentum Tips - baoquankhu1.vn
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Analyst Calls: Will Fulcrum Therapeutics Inc benefit from seasonality2025 Stock Rankings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Downgrade Watch: Can Fulcrum Therapeutics Inc disrupt its industryQuarterly Portfolio Review & Smart Money Movement Alerts - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
IPO Launch: Can Fulcrum Therapeutics Inc deliver alpha2025 Earnings Surprises & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Insider Sell: Is Canadian Imperial Bank of Commerces growth already priced in2025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen - MarketBeat
Block Trades: Is Fulcrum Therapeutics Inc part of any ETF2025 Fundamental Recap & Real-Time Volume Triggers - baoquankhu1.vn
Can Fulcrum Therapeutics Inc. disrupt its industryWeekly Trading Summary & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.8%What's Next? - MarketBeat
Whale Trades: Is Fulcrum Therapeutics Inc stock dividend yield sustainable2025 Investor Takeaways & Daily Profit Maximizing Tips - Bộ Nội Vụ
Gains Recap: Whats the fair value of Fulcrum Therapeutics Inc stock2025 Valuation Update & Safe Capital Growth Plans - baoquankhu1.vn
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co. - Defense World
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation - Nasdaq
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap UpShould You Buy? - MarketBeat
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterFootwear buying guidance for consistent weekly training mileage focuses on stable support and balance, making it a solid option for daily use. - ulpravda.ru
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Market Sentiment & Verified Entry Point Signals - Улправда
Star TribuneFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - Улправда
Will Fulcrum Therapeutics Inc. stock outperform Dow Jones indexWeekly Profit Report & Long-Term Capital Growth Strategies - Улправда
How geopolitical tensions affect Fulcrum Therapeutics Inc. stock2025 Biggest Moves & Pattern Based Trade Signal System - Улправда
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionPrice Action & Community Trade Idea Sharing Platform - ulpravda.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: A Biotech With A 90% Upside Potential - DirectorsTalk Interviews
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Currency Fluctuation Impact & Consistent Triple Returns - Улправда
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
2026 world cup results breakdown: Is Fulcrum Therapeutics Inc. stock supported by strong cash flows2026 world cup usa national team round of 32 playmakers pressing system odds analysis expert opinion - ulpravda.ru
Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould Sells 15,000 Shares - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3%Time to Sell? - MarketBeat
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):